The Dermatomycoses drugs in development market research report provides comprehensive information on the therapeutics under development for Dermatomycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dermatomycoses. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dermatomycoses and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Dermatomycoses by nine companies/universities/institutes. The top development phase for Dermatomycoses is phase ii with five drugs in that stage. The Dermatomycoses pipeline has ten drugs in development by companies and one by universities/ institutes. Some of the companies in the Dermatomycoses pipeline products market are: Vyome Therapeutics, DermBiont and Taro Pharmaceuticals USA.
The key targets in the Dermatomycoses pipeline products market include Lanosterol 14 Alpha Demethylase, Cell Wall, and Squalene Monooxygenase.
The key mechanisms of action in the Dermatomycoses pipeline product include Lanosterol 14 Alpha Demethylase Inhibitor with three drugs in Phase II. The Dermatomycoses pipeline products include three routes of administration with the top ROA being Topical and two key molecule types in the Dermatomycoses pipeline products market including Small Molecule, and Biologic.
Dermatomycoses overview
Dermatomycosis is the most common form of fungal infection of the skin and skin appendages. Areas such as the warm, humid areas of feet and spaces between toes, and armpits are often colonized by fungi. Dermatomycoses are mainly caused by filamentous fungi, which feed on the keratin present in skin, hair and nails.
For a complete picture of Dermatomycoses’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
